Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis
Alyssa A Toorop(Amsterdam Neuroscience), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), Samantha Noteboom(Université de Bordeaux), Zoé L. E. van Kempen(Amsterdam Neuroscience), Theo Rispens(Sanquin), Frederik Barkhof(Netherlands Institute for Neuroscience), Martijn D. Steenwijk(Amsterdam Neuroscience), Menno M. Schoonheim(Amsterdam Neuroscience), Bas Jasperse(Vrije Universiteit Amsterdam), J. Gravendeel(Amsterdam Neuroscience), Eva Strijbis(Amsterdam University Medical Centers)
Cited by 5
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
IgG Subclasses and Allotypes: From Structure to Effector Functions
|Frontiers in Immunology|2014|2.6k